Summary
The AI-generated content consists only of generic price/speculation and patent tracking references; it does not make dexlansoprazole prescribing-information claims (indication, dosing, contraindications, warnings, interactions, adverse reactions, or labeled administration/storage). These items cannot be verified against the supplied FDA prescribing information excerpts.
Category Scores
Accurate Statements
Dexlansoprazole is available as a generic in the U.S.
No support or refutation found in the provided FDA prescribing information excerpts.
Unsupported Statements
The exact generic price for dexlansoprazole can vary depending on strength (e.g., 30 mg vs. 60 mg).
Pricing/market variation statements are not addressed in the provided prescribing information excerpts.
The exact generic price for dexlansoprazole can vary depending on the quantity of tablets/capsules.
Pricing/market variation statements are not addressed in the provided prescribing information excerpts.
The exact generic price for dexlansoprazole can vary depending on whether payment is with insurance, a cash discount card, or without coverage.
Pricing/coverage/payment statements are not addressed in the provided prescribing information excerpts.
Dexlansoprazole cash price estimation can be based on pricing the specific NDC/product being used (strength and pack size).
NDC-based cash price estimation is not addressed in the provided prescribing information excerpts.
Prices for dexlansoprazole can differ by dose because pack pricing and manufacturer/dispensing options can change by strength.
Pricing/market mechanics are not addressed in the provided prescribing information excerpts.
60 mg formulations often cost more than 30 mg.
Specific pricing comparisons are not addressed in the provided prescribing information excerpts.
Same strength, same count, and same delayed-release formulation tend to price closer together than comparing across strengths.
Specific pricing heuristics are not addressed in the provided prescribing information excerpts.
Dexlansoprazole pricing can vary depending on whether a person pays cash versus using insurance.
Pricing/coverage statements are not addressed in the provided prescribing information excerpts.
Dexlansoprazole pricing can vary depending on pharmacy location and the specific generic product dispensed.
Pricing/location/product dispensed statements are not addressed in the provided prescribing information excerpts.
Dexlansoprazole pricing can vary depending on pack size (e.g., 30-count vs. 90-count).
Pricing/pack-size comparisons are not addressed in the provided prescribing information excerpts.
Dexlansoprazole pricing can vary depending on availability of pharmacy discount programs.
Discount-program pricing statements are not addressed in the provided prescribing information excerpts.
Dexlansoprazole pricing can change after exclusivity ends and additional generics enter.
Exclusivity/generics entry pricing dynamics are not addressed in the provided prescribing information excerpts.
DrugPatentWatch.com tracks patent and exclusivity-related developments for branded drugs.
Third-party tracking site statements are not addressed in the provided FDA prescribing information excerpts.
Contradictions
Important Omissions
No reviewable dexlansoprazole prescribing-information content was provided (e.g., labeled indications, dosing regimens, contraindications, boxed warnings, warnings/precautions, drug interactions, adverse reactions, labeled population restrictions, administration instructions, or storage).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements do not address medication safety, dosing, contraindications, drug interactions, or labeled warnings. However, they are not verifiable against the provided FDA prescribing information and include speculative pricing/general market assertions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Statements are outside the scope of the provided FDA prescribing information (pricing/third-party tracking), so label alignment cannot be established.
Suggested Improvement
Limit claims to what is stated in the FDA-approved prescribing information (sections 1–8 and related excerpts), or provide label-referenced claims (indications, dosing, contraindications, warnings/precautions, interactions, adverse reactions, and population-specific guidance) for evaluation.